T. Rowe Price Associates
CTMX icon

T. Rowe Price Associates’s CytomX Therapeutics CTMX Stock Holding History

T. Rowe Price Associates’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$556K Buy
+148,107
New +$566K ﹤0.01% 2576
2022
Q3 		– Sell
-633,418
Closed -$1.16M – 2969
2022
Q2 		$1.16M Sell
633,418
-27,645
-4% -$52.9K ﹤0.01% 1826
2022
Q1 		$1.76M Buy
661,063
+1,200
+0.2% +$4.61K ﹤0.01% 1736
2021
Q4 		$2.86M Sell
659,863
-2,802
-0.4% -$16.4K ﹤0.01% 1600
2021
Q3 		$3.37M Sell
662,665
-25,659
-4% -$137K ﹤0.01% 1577
2021
Q2 		$4.36M Sell
688,324
-1,007,942
-59% -$7.85M ﹤0.01% 1530
2021
Q1 		$13.1M Buy
1,696,266
+1,009,792
+147% +$7.99M ﹤0.01% 1351
2020
Q4 		$4.5M Sell
686,474
-200
-0% -$1.43K ﹤0.01% 1457
2020
Q3 		$4.57M Hold
686,674
– – ﹤0.01% 1413
2020
Q2 		$5.72M Buy
686,674
+276
+0% +$2.56K ﹤0.01% 1371
2020
Q1 		$5.26M Buy
686,398
+210
+0% +$1.46K ﹤0.01% 1333
2019
Q4 		$5.7M Sell
686,188
-1,518,913
-69% -$10.2M ﹤0.01% 1379
2019
Q3 		$16.3M Sell
2,205,101
-595,771
-21% -$5.88M ﹤0.01% 1209
2019
Q2 		$31.4M Sell
2,800,872
-289,801
-9% -$3.04M ﹤0.01% 1031
2019
Q1 		$33.2M Sell
3,090,673
-1,000,853
-24% -$14.8M ﹤0.01% 1017
2018
Q4 		$61.8M Buy
4,091,526
+3,923
+0.1% +$58.2K 0.01% 744
2018
Q3 		$75.6M Buy
4,087,603
+838,139
+26% +$19.1M 0.01% 765
2018
Q2 		$74.3M Buy
3,249,464
+377,032
+13% +$9.63M 0.01% 751
2018
Q1 		$81.7M Buy
2,872,432
+2,442,345
+568% +$69.7M 0.01% 699
2017
Q4 		$9.08M Buy
430,087
+120,004
+39% +$2.49M ﹤0.01% 1356
2017
Q3 		$5.63M Buy
310,083
+67,393
+28% +$1.05M ﹤0.01% 1422
2017
Q2 		$3.76M Buy
242,690
+94,385
+64% +$1.42M ﹤0.01% 1450
2017
Q1 		$2.56M Sell
148,305
-52,898
-26% -$696K ﹤0.01% 1522
2016
Q4 		$2.21M Buy
+201,203
New +$2.44M ﹤0.01% 1535
2016
Q3 		– Sell
-15,000
Closed -$153K – 2535
2016
Q2 		$153K Buy
+15,000
New +$171K ﹤0.01% 2372

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

T. Rowe Price Associates's CTMX Position: Q2 2026 in Review

T. Rowe Price Associates opened a new position in CytomX Therapeutics (CTMX) in Q2 2026: 148,107 shares worth $556K. The stake represents ﹤0.01% of the portfolio and ranks #2576 among its holdings. This is a return to the name: T. Rowe Price Associates previously reported a position in CTMX as recently as Q2 2022.

T. Rowe Price Associates first reported a position in CTMX in Q2 2016 and has held it in 25 quarters since. The position peaked at $81.7M in Q1 2018. 179 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

  • T. Rowe Price Associates held 148,107 shares of CytomX Therapeutics worth $556K as of Q2 2026.
  • CytomX Therapeutics was a new T. Rowe Price Associates position in Q2 2026.
  • CytomX Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #2576 holding.
  • T. Rowe Price Associates first reported a position in CytomX Therapeutics in Q2 2016 and has held it in 25 quarters since.
  • T. Rowe Price Associates's CytomX Therapeutics position peaked at $81.7M in Q1 2018.
  • 179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.